Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewsWire • 10/25/22
Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive DisorderGlobeNewsWire • 10/03/22
Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on PainGlobeNewsWire • 09/22/22
Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTGlobeNewsWire • 09/15/22
Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)GlobeNewsWire • 09/06/22
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVIDGlobeNewsWire • 08/22/22
Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 08/08/22
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of PainGlobeNewsWire • 08/01/22
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox InfectionGlobeNewsWire • 07/28/22
Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and DevelopmentGlobeNewsWire • 07/25/22
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive DisorderGlobeNewsWire • 07/11/22
Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USAGlobeNewsWire • 07/06/22